Perioperative Glucocorticoids in Patients With Rheumatoid Arthritis Having Total Joint Replacements: Help or Harm?
Journal
ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
13
06
2021
accepted:
22
06
2021
pubmed:
22
7
2021
medline:
22
7
2021
entrez:
21
7
2021
Statut:
ppublish
Résumé
The optimal strategy for perioperative glucocorticoid (GC) management in patients with rheumatoid arthritis (RA) on chronic GCs is unknown. Although there is a concern for hypotension if inadequate doses are used, higher GC exposure may increase perioperative complications. We aimed to investigate the relationships between perioperative GCs with hemodynamic instability and short-term postoperative complications following total hip arthroplasty (THA) and total knee arthroplasty (TKA) in patients with RA. This retrospective study included patients with RA who underwent THA and TKA. GC exposure was assessed by the total cumulative dose (in prednisone equivalents) during hospitalization. Perioperative complications and hypotension were assessed. Of 432 patients, 387 (90%) received supraphysiologic perioperative GC. Thirty percent of patients were using chronic GCs (mean daily dose, 7 ± 4 mg). Half (54%) underwent TKA. The median age was 65 years, and 79% were women. The median cumulative GC dose during hospitalization was 37 mg (interquartile range, 27-53.3). A lower cumulative dose of GC did not increase odds of hypotension during hospitalization (unadjusted odds ratio, 1.00 [95% confidence interval, 0.99-1.01]; P = 0.66)]. However, postoperative complications were higher among patients who received higher cumulative doses after adjustment for age, body mass index, home GC use, smoking, and Charlson Comorbidity Index. Risk of short-term complications increased by 8.4% (P = 0.017) for every 10-mg increase in GC dose. A lower GC dose was not associated with increased hypotension. However, patients with higher GC exposure were more likely to have hyperglycemia and other complications. These findings suggest that harms may be associated with high perioperative GC doses. Further research is needed to determine the optimal perioperative regimen for patients with RA.
Identifiants
pubmed: 34288590
doi: 10.1002/acr2.11306
pmc: PMC8449040
doi:
Types de publication
Journal Article
Langues
eng
Pagination
654-659Informations de copyright
© 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
Anaesthesia. 2020 May;75(5):654-663
pubmed: 32017012
Br J Anaesth. 2017 Feb;118(2):190-199
pubmed: 28100522
J Anaesthesiol Clin Pharmacol. 2019 Apr-Jun;35(2):147-152
pubmed: 31303699
Arthritis Rheumatol. 2017 Aug;69(8):1538-1551
pubmed: 28620948
Reg Anesth Pain Med. 2011 Jan-Feb;36(1):36-40
pubmed: 21455087
Ann Rheum Dis. 2018 Feb;77(2):281-288
pubmed: 29097373
Surgery. 2012 Aug;152(2):158-63
pubmed: 22503320
Ann Rheum Dis. 2001 Mar;60(3):214-7
pubmed: 11171680
J Arthroplasty. 2013 Sep;28(8 Suppl):11-7
pubmed: 23937923
Arthritis Res Ther. 2012 May 14;14(3):R112
pubmed: 22584017
Anaesthesia. 2019 Jul;74(7):929-939
pubmed: 30821852
J Arthroplasty. 2016 Aug;31(8):1784-7
pubmed: 26869066
Q J Med. 1967 Jul;36(143):261-76
pubmed: 6049762
Diabetes Care. 2010 Aug;33(8):1783-8
pubmed: 20435798
Arthritis Res Ther. 2015 Dec 24;17:375
pubmed: 26702817
J Rheumatol. 2018 May;45(5):604-611
pubmed: 29545451
Med J Aust. 2008 Apr 7;188(7):409-13
pubmed: 18393745
Ann Surg. 2014 Jan;259(1):32-7
pubmed: 23774314
J Bone Joint Surg Am. 1995 Dec;77(12):1801-6
pubmed: 8550646
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Diabetes Care. 2020 Jan;43(Suppl 1):S193-S202
pubmed: 31862758
Int Orthop. 2018 Mar;42(3):499-505
pubmed: 28647788
Ann Intern Med. 2019 Nov 5;171(9):680
pubmed: 31683280
Br J Anaesth. 1973 Oct;45(10):1043-8
pubmed: 4772640
Clin Exp Rheumatol. 2003 Mar-Apr;21(2):155-60
pubmed: 12747268
Ann Surg. 2015 Jan;261(1):97-103
pubmed: 25133932
Arthritis Rheum. 2005 Nov;52(11):3371-80
pubmed: 16255011
Endocr Pract. 2020 Feb;26(2):218-225
pubmed: 31652101